RYTM Rhythm Pharmaceuticals Forecast, Technical & Fundamental Analysis

RYTM's Stochastic Oscillator stays in overbought zone for 3 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RYTM broke above its upper Bollinger Band on January 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RYTM entered a downward trend on December 30, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 30, 2024. You may want to consider a long position or call options on RYTM as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on January 02, 2025. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

RYTM moved above its 50-day moving average on January 02, 2025 date and that indicates a change from a downward trend to an upward trend.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (322.581) is very high in comparison to the industry average of (15.198). P/E Ratio (0.000) is within average values for comparable stocks, (88.809). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.840). RYTM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (31.348) is also within normal values, averaging (264.909).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.